CD79A and COVID-19: In accordance with our findings, Glück et al. reported in a HCWs cohort, declining but still detectable anti-RBD IgG and IgA Abs 6 months after the second dose, while boosted COVID-19 convalescents exhibited enhanced and more stable Ab levels in the time course [38].